

IN THE CLAIMS:

Please cancel claims 1-12, without prejudice. Applicant reserves the right to pursue the subject matter of the canceled claims in a continuing application. Please amend the claims pursuant to 37 C.F.R. 1.121 as follows (see the accompanying "marked up" version pursuant to 1.121):

Please amend claims below such that claims reads as follows:

B¹

13. (Amended) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to the patient a composition comprising a haptenized or non- haptenized tumor cell or tumor cell extract comprising from about 2×10^5 to about 2.5×10^6 tumor cells or cell equivalents per dose, without any adjuvant, wherein the tumor cells or cell equivalents are conjugated to a hapten, and rendered incapable of growth or multiplication in vivo, prior to a second composition comprising an adjuvant and a tumor cell or tumor cell extract, which second composition contains (a) from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents, and (b) wherein the tumor cell or tumor cell extracts are conjugated to a hapten.

B²

16. (Amended) The method of claim 15, wherein the composition is administered four to seven days prior to the administration of cyclophosphamide.

17. (Amended) The method of claim 13, wherein the tumor cells or tumor cell extracts originate from a tumor selected from the group consisting of melanoma, ovarian cancer, colon cancer, breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.

B²
✓
18. (Amended) The method of claim 13, wherein the tumor cells or tumor cell extracts are autologous.

19. (Amended) The method of claim 13, wherein the tumor is melanoma.

20. (Amended) The method of claim 13, wherein the patient is a human.

Please add the following new claims:

25. (New) The method of claim 21, wherein the tumor cells or tumor cell extract is haptenized.

B³
26. (New) The method of claim 21, wherein the tumor cells or tumor cell extract is a mixture of haptenized and non-haptenized tumor cells or tumor cell extract.

27. (New) The method of claim 21, where at least one of the tumor cell or tumor

cell extract composition is haptenized.

28. (New) The method of claim 26, wherein the hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, ^{arsenic} arsenic acid benzene isothiocyanate, sulfanilic acid, ^{arsenic} arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

29. (New) The method of claim 28, in which the hapten is dinitrophenyl.

30. (New) The method of claim 21, wherein the tumor cell extract comprises tumor cell membrane components.

- B3 31. (New) The method of claim 21, wherein the tumor cell extract comprises tumor cell polypeptides.

32. (New) The method of claim 21, wherein the tumor cells or tumor cell extracts originate from a tumor selected from the group consisting of melanoma, ovarian cancer, colon cancer, breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.

33. (New) The method of claim 21, wherein the tumor is melanoma.

34. (New) The method of claim 21, wherein the tumor is ovarian cancer.

35. (New) The method of claim 21, wherein the tumor cell or tumor cell equivalents are rendered incapable of growth or multiplication in vivo.

36. (New) The method of claim 31, wherein the tumor cell or tumor cell equivalents are rendered incapable of growth or multiplication in vivo by irradiation.

37. (New) The method of claim 31, wherein the tumor cell or tumor cell equivalents are rendered incapable of growth or multiplication in vivo by haptenization.

B3
38. (New) The method of claim 21, wherein the adjuvant is selected from the group consisting of *Bacille Calmette-Guerin*, Q-21, and detoxified endotoxin.

39. (New) The method of claim 21, wherein the mammalian patient is a domestic pet or livestock.

40. (New) The method of claim 21, wherein the immunomodulatory agent is administered 5 to 7 days after initiation of the treatment.

41. (New) The method of claim 21, wherein the patient is a human.
42. (New) The method of claim 23, wherein the mammalian patient is a domestic pet or livestock.
43. (New) The method of claim 23, wherein the adjuvant is selected from the group consisting of *Bacille Calmette-Guerin*, Q-21, and detoxified endotoxin.
44. (New) The method of claim 23, wherein the patient is a human.
45. (New) The method of claim 23, wherein the immunomodulatory agent is administered 5 to 7 days after initiation of the treatment.
46. (New) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to the patient a composition comprising a hapttenized or a non-hapttenized tumor cell comprising from about 2×10^5 to about 2.5×10^6 tumor cells or cell equivalents per dose, without any adjuvant, wherein the tumor cells ~~or cell-equivalents are conjugated to a haptten~~, and rendered incapable of growth or multiplication in vivo, prior to a second composition comprising an adjuvant and ~~a tumor cell~~, which ~~second composition contains~~ from about 2×10^5 to about 2.5×10^6 tumor

cells or tumor cell equivalents, wherein the tumor cell or tumor cell equivalents are conjugated to a hapten.

47. (New) The method of claim 46, wherein the hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

48. (New) The method of claim 46, wherein the tumor is melanoma.

49. (New) The method of claim 46, wherein the tumor is ovarian cancer.

163 ✓
50. (New) The method of claim 46, wherein the adjuvant is selected from the group consisting of *Bacille Calmette-Guerin*, Q-21, and detoxified endotoxin

51. (New) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to the patient:

(a) on the first day of the treatment, a composition comprising autologous tumor cells, which corresponds to from about 2×10^5 to about 2.5×10^6 tumor cells, free of any adjuvant;

(b) four to seven days after initiation of the treatment, an immunomodulatory

agent that potentiates protective anti-tumor immunity or inhibits immune suppression,
or both; and

(c) at least one additional composition comprising autologous tumor cells.

52. (New) The method of claim 51, wherein the tumor is melanoma.

53. (New) The method of claim 51, wherein the tumor is ovarian cancer.

54. (New) The method of claim 51, wherein the adjuvant is selected from the group
consisting of *Bacille Calmette-Guerin*, Q-21, and detoxified endotoxin

B3
55. (New) A method for inducing an anti-tumor response in a mammalian patient
suffering from a tumor, which method comprises administering to the patient:

(a) on the first day of the treatment, a composition comprising a haptenized
autologous tumor cell which corresponds to from about 2×10^5 to 2.5×10^6 tumor
cells free from any adjuvant;

(b) four to seven days after initiation of the treatment, cyclophosphamide; and

(c) at least one week after initiation of the treatment, a composition comprising
an adjuvant and a haptenized autologous tumor cell which corresponds to from about
 2×10^5 to about 1×10^7 tumor cells.